(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of 54.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Stoke Therapeutics's revenue in 2026 is $32,080,000.On average, 15 Wall Street analysts forecast STOK's revenue for 2026 to be $2,030,942,488, with the lowest STOK revenue forecast at $976,576,350, and the highest STOK revenue forecast at $3,838,729,806. On average, 13 Wall Street analysts forecast STOK's revenue for 2027 to be $3,256,084,923, with the lowest STOK revenue forecast at $1,220,720,438, and the highest STOK revenue forecast at $6,866,552,464.
In 2028, STOK is forecast to generate $8,040,561,661 in revenue, with the lowest revenue forecast at $4,992,746,591 and the highest revenue forecast at $14,066,311,782.